Skip to main content
. 2021 Jun 19;297(1):100900. doi: 10.1016/j.jbc.2021.100900

Figure 1.

Figure 1

MIR2 can regulate CD86 bearing a nondescript transmembrane domain, while MARCH1 cannot.A, left, cartoon showing architecture of CD86, MARCH1, and MIR2. Right, schematic of lentiviral expression vectors for constitutively expressed CD86- and DOX-inducible MARCH1 and MIR2. B, the ability of MARCH1 and MIR2 to downregulate WT CD86 was compared with their ability to downregulated CD86 carrying a polyvaline TMD. C, susceptibility scores calculated from five biological replicates (each done in technical triplicates) of the plots shown in B. MARCH1 is reliant on the TMD of CD86 for activity, whereas MIR2 is not. DOX, doxycycline; MARCH1, membrane-associated RING-CH; MIR2, modulator of immune recognition.